-transparent.png){kind=logo}
We present four patients with non-small cell lung cancer treated in second and third line with Erlotinib. These are selected patients that obtained a good clinical response. Almost all presented cutaneous side effects. Rev Port Pneumol 2008; XIV (Supl 3): S65-S69.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Jorge Dionísio, and
Teresa Almodôvar, and
Dina Matias, and
Paula Ferreira, and
Paulo Mota, and
J Duro da Costa
September 2018,
Anti-cancer drugs,
Jorge Dionísio, and
Teresa Almodôvar, and
Dina Matias, and
Paula Ferreira, and
Paulo Mota, and
J Duro da Costa
October 2008,
Revista portuguesa de pneumologia,
Jorge Dionísio, and
Teresa Almodôvar, and
Dina Matias, and
Paula Ferreira, and
Paulo Mota, and
J Duro da Costa
July 2005,
The New England journal of medicine,
Jorge Dionísio, and
Teresa Almodôvar, and
Dina Matias, and
Paula Ferreira, and
Paulo Mota, and
J Duro da Costa
March 2006,
Drugs of today (Barcelona, Spain : 1998),
Jorge Dionísio, and
Teresa Almodôvar, and
Dina Matias, and
Paula Ferreira, and
Paulo Mota, and
J Duro da Costa
July 2009,
Respirology (Carlton, Vic.),
Jorge Dionísio, and
Teresa Almodôvar, and
Dina Matias, and
Paula Ferreira, and
Paulo Mota, and
J Duro da Costa
January 2012,
Journal of cancer research and therapeutics,
Jorge Dionísio, and
Teresa Almodôvar, and
Dina Matias, and
Paula Ferreira, and
Paulo Mota, and
J Duro da Costa
September 2010,
The Korean journal of internal medicine,
Jorge Dionísio, and
Teresa Almodôvar, and
Dina Matias, and
Paula Ferreira, and
Paulo Mota, and
J Duro da Costa
December 2014,
Oncology letters,
Jorge Dionísio, and
Teresa Almodôvar, and
Dina Matias, and
Paula Ferreira, and
Paulo Mota, and
J Duro da Costa
June 2011,
Gan to kagaku ryoho. Cancer & chemotherapy,
Jorge Dionísio, and
Teresa Almodôvar, and
Dina Matias, and
Paula Ferreira, and
Paulo Mota, and
J Duro da Costa
October 2007,
Expert opinion on pharmacotherapy,
